4 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $9.12 | $9.47 | +3.9% | Beat |
| Q4 2025 | 2025-12-31 | $10.83 | $11.44 | +5.7% | Beat |
| Q3 2025 | 2025-09-30 | $9.78 | $11.83 | +21.0% | Beat |
| Q2 2025 | 2025-06-30 | $8.61 | $12.89 | +49.8% | Beat |
Earnings Beat Rate
Regeneron Pharmaceuticals has beaten analyst EPS estimates in 4 of 4 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →